Market research
0950.HK Lee's Pharmaceutical Holdings Limited
HK HKD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 671M
- P/E ratio
- 7.12
- Analyst target
- 1
- Dividend yield
- 3.9%
- Beta
- 0.57
Profile
Company facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- KYG5438W1116
- Market cap
- 671M
- P/E ratio
- 7.12
- Analyst target
- 1
- Dividend yield
- 3.9%
- Beta
- 0.57
About
About Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0950.HK discussion.
5 years, 5 months ago
Lee's Pharmaceutical Holdings Limited is currently in a long term downtrend where the price is trading 9.9% below its 200 day moving average.
From a valuation standpoint, the stock is 97.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.
Lee's Pharmaceutical Holdings Limited's total revenue rose by 5.8% to $323M since the same quarter in the previous year.
Its net income has dropped by 83.8% to $7M since the same quarter in the previous year.
Finally, its free cash flow fell by 172.8% to $-29M since the same quarter in the previous year.
Based on the above factors, Lee's Pharmaceutical Holdings Limited gets an overall score of 2/5.